Minor Cannabinoids CBC and CBG Show Antitumor Activity Against Aggressive Brain Cancer Cells
CBC and CBG had strong binding to glioblastoma targets and killed brain cancer cells across multiple cell lines.
Quick Facts
What This Study Found
CBC, CBG, and CBD demonstrated strong binding to GPR55 and PINK1 glioblastoma targets. Confirmed cytotoxic effects on glioblastoma cell lines. Differential GPR55/PINK1 expression in tumor vs. normal tissue.
Key Numbers
Three glioblastoma cell lines tested. Strong binding to GPR55 and PINK1. All three cannabinoids showed cytotoxic effects.
How They Did This
Molecular docking, cell viability assays on multiple brain cancer cell lines, plus transcriptomic analysis.
Why This Research Matters
Glioblastoma has median survival of 15 months. Minor cannabinoids may offer new therapeutic avenues.
The Bigger Picture
CBC and CBG deserve attention alongside THC and CBD in cancer research, with GPR55 and PINK1 as targetable pathways.
What This Study Doesn't Tell Us
In vitro only. Blood-brain barrier not addressed. No comparison with standard treatments.
Questions This Raises
- ?Could CBC or CBG cross the blood-brain barrier?
- ?Would combining with temozolomide improve outcomes?
Trust & Context
- Key Stat:
- Evidence Grade:
- Multi-method approach but in vitro only.
- Study Age:
- 2025 in silico to in vitro study of minor cannabinoids against glioblastoma.
- Original Title:
- Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds from Cannabis sativa and Piper nigrum Against Malignant Glioma: An In Silico to In Vitro Approach.
- Published In:
- International journal of molecular sciences, 26(12) (2025)
- Authors:
- Turizo Smith, Andrés David, Montoya Moreno, Nicolás, Rodríguez-García, Josefa Antonia, Marín-Loaiza, Juan Camilo, Arboleda Bustos, Gonzalo
- Database ID:
- RTHC-07831
Evidence Hierarchy
Frequently Asked Questions
Can cannabinoids fight brain cancer?
CBC, CBG, and CBD killed glioblastoma cells in the lab. Early findings not yet tested in animals or humans.
What are CBC and CBG?
Non-psychoactive minor cannabinoids increasingly studied for therapeutic properties.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-07831APA
Turizo Smith, Andrés David; Montoya Moreno, Nicolás; Rodríguez-García, Josefa Antonia; Marín-Loaiza, Juan Camilo; Arboleda Bustos, Gonzalo. (2025). Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds from Cannabis sativa and Piper nigrum Against Malignant Glioma: An In Silico to In Vitro Approach.. International journal of molecular sciences, 26(12). https://doi.org/10.3390/ijms26125688
MLA
Turizo Smith, Andrés David, et al. "Evaluating the Antitumor Potential of Cannabichromene, Cannabigerol, and Related Compounds from Cannabis sativa and Piper nigrum Against Malignant Glioma: An In Silico to In Vitro Approach.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms26125688
RethinkTHC
RethinkTHC Research Database. "Evaluating the Antitumor Potential of Cannabichromene, Canna..." RTHC-07831. Retrieved from https://rethinkthc.com/research/turizo-2025-evaluating-the-antitumor-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.